All Drug Repurposing articles
-
NewsWhy cancer drug CADD522 could offer a new route to treating osteoporosis
A compound originally designed to block a cancer-associated protein has demonstrated unexpected benefits for bone health and metabolism in post-menopausal mice, suggesting a potential new mechanism for osteoporosis drug discovery.
-
NewsNew LOX target discovery could help overcome chemotherapy-resistant breast cancer
A preclinical study has identified lysyl oxidase as an intracellular survival factor in triple-negative breast cancer, with researchers demonstrating that sequentially blocking LOX and a compensatory ferroptosis defence pathway significantly suppresses tumour growth without chemotherapy.
-
NewsBlood metabolite links ALS progression rate to potential treatment target
A metabolic signal detectable in patient blood has been linked to ALS progression rate and survival, with preclinical data suggesting that boosting levels of the molecule could protect motor neurons and extend survival in disease models.
-
NewsBRAF identified as novel target for neuropathic pain treatment
Researchers at MD Anderson Cancer Center have discovered that BRAF, a protein well known for its role in cancer, may also drive chronic pain following nerve injury – raising the prospect of repurposing approved cancer drugs as treatments for neuropathic pain.
-
NewsStem cell-grown kidney organoids could help uncover new treatments for AKI
Researchers at Monash University have grown miniature human kidneys from stem cells that could give drug discovery teams a more human-relevant model for investigating acute kidney injury and identifying therapies that promote tissue recovery.
-
ArticleWhy researchers are revisiting bisantrene decades after it was abandoned
An oncology drug abandoned decades ago is getting a second look, with new research uncovering a mechanism that could offer an alternative route to targeting MYC, one of cancer’s toughest targets.
-
ArticleWhy inherited retinal disease treatment requires more than gene therapy
Most inherited retinal diseases still have no approved therapy despite advances in gene therapy. This article explores why researchers are targeting shared disease mechanisms alongside individual mutations.
-
ArticleInside one of the most comprehensive human proteome atlases to date
Understanding where proteins are expressed throughout the body is critical for selecting better drug targets. Here’s how a new human proteome atlas could improve target selection, predict toxicity and support drug repurposing.
-
NewsNew drug SB-0110 targets levodopa’s two biggest clinical limitations for Parkinson’s
A computational biology-derived compound has shown promise in preclinical models by simultaneously improving levodopa response and reducing dyskinesia — two of the most significant challenges in long-term Parkinson’s disease management.
-
NewsPancreas organoids reveal CFTR dysfunction as chronic pancreatitis drug target
Researchers at the Salk Institute have developed a patient-derived organoid platform that identifies distinct biological subtypes of chronic pancreatitis and highlights CFTR as a potential therapeutic target, raising prospects for more personalised treatments.
-
NewsKCL-286 targets multiple Alzheimer’s pathways in preclinical study
A repurposed small molecule originally developed for spinal cord injury has demonstrated the ability to address multiple disease-relevant pathways in Alzheimer’s disease, including DNA damage and neuroinflammation, offering a potential route to disease-modifying therapy.
-
News15-PGDH enzyme inhibition protects brain cells in Parkinson’s disease models
Researchers have identified 15-PGDH enzyme inhibition as a neuroprotective strategy in Parkinson’s disease, with repurposable compounds already in clinical development offering a potential shortcut to disease-modifying therapies.
-
NewsEpilepsy drug sodium valproate could improve vaccine immune responses
A commonly prescribed epilepsy drug has shown striking potential as a vaccine booster in a controlled human trial, more than doubling antibody levels and increasing T cell responses tenfold at a fraction of its standard therapeutic dose.
-
NewsTranexamic acid cuts post-hepatectomy liver failure risk threefold
An international multi-centre study has found that tranexamic acid, a widely available and inexpensive haemostatic agent, could reduce the risk of post-hepatectomy liver failure threefold, offering a potential new preventive strategy for one of liver surgery’s most feared complications.
-
NewsAI uncovers antimicrobial peptides hidden within prion proteins
Researchers at the University of Pennsylvania have used artificial intelligence to identify a new class of antimicrobial peptides within prion proteins, traditionally associated with neurodegenerative disease. The discovery reveals 1,179 potential antibiotic candidates, with laboratory and animal studies confirming activity against drug-resistant bacterial strains.
-
NewsThalidomide shows potential for treating rare brain vascular malformations
Researchers in China have reported encouraging preclinical and early clinical evidence that thalidomide may help stabilise and reduce rare vascular malformations affecting the brain and spinal cord, potentially offering the first medical treatment option for patients with central nervous system arteriovenous malformations who are unsuitable for invasive procedures.
-
NewsPim1 kinase identified as therapeutic target for inflammatory arthritis
Researchers have identified Pim1 kinase as a critical driver of inflammatory arthritis through its regulation of Th17 cell differentiation via mitochondrial metabolism.
-
NewsNew kidney water regulation mechanism could improve polycystic kidney disease treatment
Scientists at Mayo Clinic have discovered a previously unknown mechanism by which kidneys regulate water balance, offering new therapeutic possibilities for polycystic kidney disease patients experiencing severe side effects from current treatments.
-
ArticlePomegranate-derived compound shows therapeutic potential in heart disease
Researchers at Cardiff University have identified urolithin A – a compound produced by gut bacteria during the metabolism of substances found in pomegranates – as a new approach for treating cardiovascular disease.
-
NewsStudy suggests senolytic therapies could slow spinal disc degeneration
Thomas Jefferson University researchers have demonstrated that senolytic therapies targeting cellular senescence may delay early intervertebral disc degeneration, a major cause of chronic back and neck pain.